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ommon Sense, Dollars and
ents, and Drug-Eluting Stents*
aul T. Vaitkus, MD, MBA, FACC
ockford, Illinois
ew technologies in medicine almost always bring higher
osts to the medical system. Most new medical technologies
o not offer cost offsets via prevention of subsequent
pisodes of illness or reductions in labor costs. Two papers
n the current issue of the Journal (1,2) document an
xception to the rule of purely increased costs of a new
echnology. However, despite demonstrating offsetting cost
avings within the overall health-care delivery system, when
laced in the context of the complicated American medical
ystem, these two papers serve to underscore serious ineq-
ities of who bears the costs and who reaps the benefits.
See pages 253 and 262
Drug-eluting stents (DESs), as is now well known to
ardiologists, are substantially more expensive than their
redecessors. The two papers published in the current issue
1,2) provide quantitative economic data that supports the
ommon-sense notion that DESs, by preventing recurrent
ardiovascular events (primarily repeat revascularization),
ffer a downstream savings that warrant the up-front initial
reater investment. The paper of Bakhai et al. (1) builds on
bservations previously published on sirolimus-eluting
tents (3) and showed that, in comparison to a bare-metal
tent (BMS), a paclitaxel-eluting stent reduced long-term
osts as it reduced restenosis. The long-term cost benefit
ffset the initially higher costs of the DES. The manuscript
f Elezi et al. (2) compares the two commercially available
ESs and reports that insofar as a sirolimus-eluting stent
ay be superior to a paclitaxel-eluting stent in preventing
estenosis (a notion still under debate) (4–7), it will have
uperior long-term cost advantages. Insofar as other recently
eported trials demonstrated no relative advantage of one
tent over the other (8), one would expect that cost analyses
rom such neutral studies will demonstrate economic
eutrality as well. No doubt the results of Elezi et al. (2) will
e the topic of much spin-doctoring by the two manufac-
urers on the opposite sides of the debate.
Interpretation of the findings of Bakhai et al. (1) and
lezi et al. (2) is entirely dependent on one’s perspective in
he medical system (9). We will limit our discussion to three
implified stakeholders: payers, providers (i.e., hospitals),
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theP
merican College of Cardiology.
From Midwest Heart Associates, Rockford, Illinois.nd vendors. Equally simply, we can consider these stake-
olders in a sequential chain (payer to hospital to vendor) in
hich one party’s costs represent the next party’s revenues.
herein lie the nettlesome economic issues.
Elezi et al. (2) adopt the perspective of payer and
onsistently maintain it throughout their analysis. The fact
hat their data were gathered in Germany does not mean
hey are less relevant for the U.S. Although the cost
tructures of the two systems certainly differ, the direction-
lity of their analysis is nevertheless generalizable. A repeat
ospitalization prevented is a large cost avoided on either
ide of the Atlantic. A DES costs more than a BMS in the
.S. and the European Union alike.
Bakhai et al. (1) incorrectly state that they adopt “soci-
ty’s” perspective in that the costs they account for are not
society’s” costs at all. The costs they assess for the initial
pisode of care are for the hospital, and the follow-up costs
hey consider largely reflect those of payers. These do not
um to “society’s” costs, as the latter would include such
iverse elements as lost productivity for the patients and all
irect and indirect costs of providing health care. The latter
re two or more orders removed from the hospital’s cost
tructures. The perspective of Bakhai et al. (1) is thus
mbiguous and does not accurately represent any player in
he marketplace, but perhaps is best approximated by the
ayer’s.
The main difference between all of the published eco-
omic analyses of DESs (3,10,11), including the papers of
lezi et al. (2) and Bakhai et al. (1), and the real world is
hat in the protocol-driven environment, essentially only a
ingle stent was implanted. In the real world, the average
umber of stents per case is closer to 2. Thus the disparity
etween the up-front costs of DESs and BMSs is substan-
ially greater in clinical practice than in the published
conomic analyses. The notion that the reduction in late
osts offsets the initial costs is very sensitive to even small
hanges in the number of stents implanted or the restenosis
ates (3), and therefore the “cost neutral” conclusion of
akhai et al. (1) may not be applicable outside the confines
f the TAXUS-IV (Treatment of De Novo Coronary
isease Using a Single Paclitaxel-Eluting Stent) trial.
How DESs impact costs in the real world is driven to a
reat degree by multi-vessel disease. The up-front higher
osts of DESs and the downstream reduction of costs are
oth magnified. The up-front costs of DESs, however, need
o be considered relative to coronary artery bypass grafting
CABG), which is an even more expensive alternative.
lthough the real assessment of the relative costs of multi-
essel DESs versus CABG will have to wait until the
ompletion of newly launched prospective clinical trials of
ulti-vessel revascularization (12,13), data modeling based
n ARTS-II (Arterial Revascularization Therapies Study
art II: Sirolimus-Eluting Stents for the Treatment of
atients With Multivessel De Novo Coronary Artery
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July 18, 2006:268–9 Editorial Commentesions) suggests that the stent strategy will likely have the
verall economic advantage (14).
INNERS AND LOSERS
iagnosis-related group (DRG)-driven payers (such as
edicare) are winners in this game. They bear a fixed,
ontrolled, increased up-front cost (which barely covers the
ncremental cost of a single DES), which is then largely
ffset by downstream savings of fewer repeat hospitaliza-
ions. This is illustrated in the last paragraph of the Results
ection in the paper by Bakhai et al. (1): Medicare saved
lightly more than $200 per percutaneous coronary inter-
ention (PCI) patient. Commercial payers who pay a
iscounted fee for service (usually a negotiated percentage of
harges) are not as fortunate. Unlike Medicare, they help
ay for most of the freight. Interventional cardiologists have
emonstrated that their behaviors are generally cost insen-
itive. They may complain about the costs (of BMSs in 1995
r DESs in 2004), but, motivated by offering their patients
he greatest technical and clinical advances, they will not
esitate to utilize the more expensive technologies. The
endors currently enjoy an oligopolistic pricing opportunity
nd have acted accordingly. The hospitals, on the other
and, bear the greater DES acquisition cost and also suffer
downstream opportunity loss as repeat revascularization is
voided. In the analysis of Bakhai et al. (1) of an artificial
AXUS-IV universe of single-vessel disease treated with a
ingle DES, the hospital loses approximately $450 per PCI
atient. For an institution that performs 500 PCIs per year,
hat’s $250,000. In the real-world setting of multi-stent
ases and multi-vessel disease, the DES PCI is an even
igger money-loser, and a CABG avoided (either in the first
lace or later downstream) is a large lost revenue for the
ospital. Drug-eluting stents have a much worse impact on
ospital finances than the arithmetic of Bakhai et al. (1)
ould suggest.
What could be done to rectify these inequities? The
enter for Medicare and Medicaid Services regularly re-
iews data on actual costs associated with specific DRGs
nd adjusts payments accordingly. This process should
artially address the problem confronting hospitals, albeit
ith a substantial time lag. Stent manufacturers, on the
ther hand, will largely respond only to market forces and
ot appeals to altruism. As new players enter the market and
ESs are relegated to the status of commodities, more
ompetitive pricing will inevitably come into play. Forward-
ooking vendors will anticipate this and attempt to solidify
heir relationships with their customers by offering creative
ricing strategies. One particularly attractive option would
e for the vendors to provide all DESs per PCI case,
egardless of the number used, for the price of two DESs.
here will still be plenty of immediate profit and extended
ong-term benefits to the vendors in developing lasting
artnerships with providers. Whether recent merger and
cquisition activity among the key manufacturers will serveo stifle competition warrants intense Federal Trade Com-
ission scrutiny.
Finally, it deserves repeating that in undertaking analyses
uch as those of Bakhai et al. (1) and Elezi et al. (2), it is
ritical to clearly specify the perspective in health economics
esearch, and to do one’s accounting at a corresponding level
14). This is not, however, sufficient. All such research
hould be extended to assess the impact on all stakeholders
n the market and to undertake sensitivity analysis on the
linical and economic inputs that affect the measured
utcomes. It no longer suffices to declare that a treatment
odality is “cost effective” or “cost neutral” or “cost advan-
ageous” without specifying: “For whom?” and “Under what
ircumstances?”
eprint requests and correspondence: Dr. Paul T. Vaitkus,
idwest Heart Associates, Renaissance Plaza, 1340 Charles Street,
uite 300, Rockford, Illinois 61104. E-mail: pvaitkus@uic.edu.
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